Kura Oncology, Inc. — Form 10-Q Summary
Business context and reporting period
Kura Oncology is a clinical-stage biopharmaceutical company developing precision oncology medicines. Its principal clinical programs were tipifarnib and KO-539; the KO-947 ERK inhibitor program was terminated during 2020. The filing covers the quarter and nine months ended September 30, 2020, and was filed November 5, 2020. The financial statements are unaudited and presented under U.S. GAAP.
Financial condition and key metrics
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $16.6 million | $42.9 million |
| General and administrative expense | $7.6 million | $22.7 million |
| Total operating expenses | $24.2 million | $65.6 million |
| Other income, net | $0.4 million | $2.1 million |
| Net loss | $23.8 million | $63.5 million |
| Net loss per share, basic and diluted | $0.42 | $1.24 |
| Net cash used in operating activities | Not separately presented | $51.5 million |
The company has no approved products and therefore has not generated product-sales revenue. Gross margin and operating margin are not meaningful or clearly provided because the company has no product revenue. Accumulated deficit was $276.3 million at September 30, 2020.
At September 30, 2020, cash and cash equivalents were $77.0 million, short-term investments were $248.5 million, and cash, cash equivalents and short-term investments totaled approximately $325.4 million. Total current assets were $328.9 million and total assets were $339.6 million. Stockholders’ equity was $306.5 million.
Debt consisted of $7.5 million of term loans, including $2.5 million classified as current and $5.0 million classified as long term. The company could draw up to an additional $12.5 million under its Silicon Valley Bank facility through November 30, 2020. The term loans mature May 1, 2023, bear interest at the greater of 5.50% or prime plus 0.25%, and include a final payment equal to 7.75% of drawn amounts.
Material changes versus the prior comparable period
- Third-quarter net loss increased to $23.8 million from $16.4 million; nine-month net loss increased to $63.5 million from $45.3 million.
- Third-quarter research and development expense increased $4.1 million, or approximately 32%, primarily from KO-539 clinical-trial and manufacturing activities and higher personnel and other costs. Nine-month R&D expense increased $8.5 million, or approximately 25%.
- Third-quarter general and administrative expense increased $2.5 million, or approximately 48%; the nine-month increase was $8.5 million, or approximately 60%, driven by pre-commercial planning, share-based compensation, professional and legal fees, and personnel costs.
- Interest income and total other income declined as interest rates and the composition of investments reduced investment returns.
- Operating cash use increased to $51.5 million from $40.8 million for the nine-month period. Investing cash use increased to $39.7 million, partly due to property and equipment purchases.
- Financing cash inflow increased to $142.3 million from $110.5 million, primarily reflecting the May 2020 public offering. The offering sold 10.465 million shares and generated approximately $134.9 million of net proceeds.
- Shares outstanding increased to 56.6 million at September 30, 2020 from 45.4 million at December 31, 2019, reflecting the public offering and equity-plan activity.
- Operating lease obligations increased substantially following new San Diego and Boston office leases. Total operating lease liabilities were $7.9 million at September 30, 2020 versus approximately $0.3 million at December 31, 2019.
Guidance, outlook, commentary and risks
Management stated that existing cash, cash equivalents and short-term investments were expected to fund operating expenses and capital requirements into 2023 based on current plans. The company nevertheless expects significant additional financing will be required. It had a $75.0 million at-the-market equity facility available, but had not sold shares under that facility as of the filing.
Management expected R&D and G&A expenses to increase as clinical development and pre-commercial activities continued. The company expected to determine a recommended Phase 2 dose for KO-539 in the first quarter of 2021 and planned to advance into genetically defined expansion cohorts if successful.
The AIM-HN registration-directed trial of tipifarnib was amended to enroll patients with any HRAS mutation, expanding the evaluable population. Because of the expanded enrollment requirement and COVID-19-related disruptions, the company could not reasonably forecast when the trial would be fully enrolled.
- COVID-19 slowed patient screening and enrollment, disrupted clinical-site operations, and could affect contract research organizations, manufacturers, suppliers and regulatory timelines.
- The company remains dependent on successful clinical development, regulatory approval and commercialization of tipifarnib and KO-539. Neither candidate had been approved for marketing.
- Clinical results may not be predictive of later-stage outcomes; trials may face enrollment delays, safety issues, protocol changes, manufacturing problems or regulatory holds.
- Companion diagnostics are expected to be important or required for tipifarnib in HRAS-mutant head and neck cancer and KO-539 in genetically defined AML. Diagnostic development, approval, reimbursement and adoption remain risks.
- The company relies on third parties for clinical trials, manufacturing, data management and diagnostic development, limiting its operational control.
- Additional equity or debt financing may be unavailable or dilutive. The term-loan agreement includes restrictive covenants and substantially secures the lender’s interests with company assets other than intellectual property.
- Tipifarnib’s composition-of-matter patents have expired in the United States and Europe; commercial protection therefore depends substantially on method-of-use patents and regulatory exclusivity.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Management concluded that disclosure controls and procedures were effective as of September 30, 2020.
Most important facts for investors to verify
- Whether cash resources and the stated funding horizon remain adequate after subsequent clinical spending, operating losses and any financing activity.
- Enrollment progress, timing and efficacy results for the AIM-HN tipifarnib trial, including the effect of COVID-19 and the broader HRAS eligibility criteria.
- KO-539 safety, activity and dose-selection results, including the planned Phase 2 expansion strategy.
- Availability and terms of any additional debt or equity financing, including potential dilution and the status of the ATM facility.
- Development and regulatory progress for required or anticipated companion diagnostics.
- Changes in clinical-trial costs, contract-manufacturing capacity, supply continuity and regulatory timelines.
- Outstanding equity dilution sources, including approximately 5.1 million options excluded from diluted loss-per-share calculations, a 33,988-share warrant, and shares reserved under equity plans.